Self-Funded Search: Medical Supply Acquisition Playbook

Medical Supply Valuation by Product Category

Medical supply businesses are not one category — they're a spectrum, and valuation varies widely by product mix and revenue predictability.

**Durable Medical Equipment (DME):** Wheelchairs, hospital beds, CPAP devices, walkers, mobility aids. These businesses bill Medicare, Medicaid, and private insurance. Rental revenue (monthly billing for equipment on loan) is recurring and sticky. Valuation: 3x–5x EBITDA. The multiple is constrained by reimbursement rate risk — Medicare can change what it pays for a CPAP rental, and that directly impacts EBITDA.

**Specialty pharma distribution:** Specialty drug distribution to clinics, infusion centers, and specialty pharmacies. Higher margin, more complex compliance. Valuation: 4x–7x EBITDA. The premium reflects contractual supplier relationships and specialty drug access, which are hard to replicate.

**Medical consumables:** Disposable supplies — gloves, bandages, wound care, surgical supplies — sold to hospitals, clinics, and nursing homes. Contract-based, high volume, low margin. Valuation: 2x–4x EBITDA. GPO contracts are the moat; without them, you're competing on price alone.

**Home medical equipment:** Overlaps with DME but specifically serves homebound patients. Medicare Advantage penetration is growing in this segment, which creates reimbursement risk alongside revenue growth. Valuation: 3x–4.5x EBITDA.

Buyers should model EBITDA after normalizing for owner comp, one-time equipment purchases, and above-market owner salaries typical in closely-held medical businesses. The seller paid himself $280K/year; market-rate replacement is $120K. That $160K difference is real EBITDA add-back.

• DME (wheelchairs, CPAP, mobility): 3x–5x EBITDA
• Specialty pharma distribution: 4x–7x EBITDA
• Medical consumables: 2x–4x EBITDA
• Home medical equipment: 3x–4.5x EBITDA

GPO Contracts as Competitive Moat

Group Purchasing Organizations (GPOs) — Vizient, Premier, Intalere, Provista — aggregate purchasing power for hospitals, health systems, and clinics. A medical supply company with a GPO contract has pre-negotiated pricing access to thousands of hospital purchasing departments that would otherwise require direct sales relationships to reach.

GPO membership is not transferable by default. This is a critical due diligence point. When you acquire a medical supply business, the GPO contracts assigned to the seller's legal entity need to be re-credentialed or assigned to your acquiring entity. Some GPOs allow novation within 90 days of a change of control with minimal friction. Others require full re-application, references, and financial review of the buyer. Timeline: 60–120 days to maintain existing GPO access post-close.

The diligence question to ask before LOI: get the GPO contract assignment provisions in writing and call the GPO's supplier relations team directly to confirm the process. A deal where you lose your two GPO contracts during the transition window is a deal where you lose 30–50% of your revenue pipeline for three months.

For buyers with industry relationships, GPO membership is also a competitive advantage in sourcing deals. Medical supply owners who participate in GPO supplier conferences are addressable through industry channels — healthcare distributor associations, regional medical trade shows — that most financial buyers don't use.

• Confirm GPO contract assignment provisions before signing LOI
• Call GPO supplier relations team directly — don't rely on seller's summary
• Budget 60–120 days for GPO re-credentialing post-close
• Vizient, Premier, Provista — each has different assignment processes

FDA and DEA Regulatory Requirements

Medical supply businesses operate under layered federal oversight. Understanding what applies to your target is essential before you make an offer — some licenses don't transfer, some require significant lead time, and some trigger reapplication requirements that can extend closing timelines or require escrow holdbacks.

**FDA Registration:** Any company that manufactures, repackages, or distributes medical devices is required to register with the FDA as a medical device establishment. Most distributors of finished medical devices (not manufacturers) are exempt from 510(k) premarket requirements but must maintain FDA establishment registration. This does transfer with a change of control — the registered establishment continues, the owner changes. Notify FDA within 30 days of ownership change.

**DEA Registration:** Applicable only to businesses distributing controlled substances. Pharmaceutical distributors handling Schedule II–V controlled substances must maintain a DEA distributor registration. This does NOT transfer automatically. A new owner must apply for a new DEA registration before distributing controlled substances — process takes 60–90 days and requires background checks. If you need DEA registration continuity for operations, structure the deal with a delayed closing and DEA approval as a closing condition, or operate the controlled substance segment under the seller's registration via a management agreement during the transition period (this requires careful legal structuring).

**Medicare/Medicaid Billing Number (NPI/PTAN):** For DME businesses that bill CMS directly, the PTAN (Provider Transaction Access Number) is associated with the legal entity and accreditation. Change of ownership (CHOW) requires filing CMS Form 855A/S and can take 90–180 days for CMS to process, during which billing may be interrupted. Work with a healthcare reimbursement attorney pre-LOI to map out the CHOW timeline for your specific state and product category.

• FDA registration: transfers with entity, notify within 30 days of close
• DEA registration: does NOT transfer — new owner must apply (60–90 days)
• CMS PTAN/Medicare billing: CHOW process 90–180 days, interruption risk
• State pharmacy licenses: varies by state, most require re-application at change of control

SBA Financing for Medical Supply Acquisitions

Medical supply distribution is SBA 7(a) eligible — healthcare product distribution falls within SBA's approved industry list. The goodwill allowance (up to 50% of loan) applies here too, which is relevant because customer relationships, GPO contracts, and billing credentials constitute meaningful intangible value.

Practical financing structure for a $2M medical supply acquisition:

**Equity injection:** 15–20% for most deals ($300K–$400K). If real estate is included, the blended injection can be lower due to better collateral coverage on the real estate portion.

**Loan term:** 10 years for working capital and goodwill components. Inventory-heavy businesses may have additional ABL (asset-based lending) structure on top of SBA for inventory financing.

**Regulatory escrow:** Consider a holdback of 5–10% of purchase price in escrow pending successful CMS CHOW approval, DEA re-registration (if applicable), and GPO contract re-credentialing. This is standard in healthcare acquisitions and protects both buyer and seller.

**DSCR expectations:** Medical supply businesses often have EBITDA margins of 12–22% depending on category. At $420K EBITDA on a $1.7M SBA loan (10-year, 10.5%), annual debt service is approximately $221K — DSCR of 1.90x. That's a comfortable underwriting story.

For the full SBA 7(a) acquisition financing framework, including how to select SBA preferred lenders with healthcare sector experience.

Self-Funded Search vs. PE-Backed: Competitive Positioning

PE-backed medical supply platforms (McKesson, Cardinal Health, regional strategics) are buying at 5x–8x EBITDA for businesses with $5M+ EBITDA. They're not competing for the $300K–$700K EBITDA business you're looking at. That market is largely yours.

Self-funded search competitive advantages in medical supply:

**Speed.** PE platforms move at institutional pace — 4–6 months from first call to close. A motivated seller who wants out in 60–90 days chooses the self-funded buyer who can close. Have your SBA pre-approval, legal team, and diligence checklist ready before you start calling.

**Relationship with the owner.** Most small medical supply distributors were built by one person over 15–25 years. They have real relationships with hospital purchasing managers, clinic administrators, and GPO reps. They want to sell to someone who will maintain those relationships, not a platform that will rebrand and systematize everything. Positioning as an operator-buyer who will run the business personally resonates strongly.

**No management consulting fee.** PE transactions include advisory fees, management fees, and legal costs that can total $150K–$400K on a $3M deal. Self-funded deals run $30K–$80K in total transaction costs. That cost difference can be shared with the seller as a higher purchase price — a real competitive advantage in a direct deal.

For a full due diligence checklist applicable to medical supply deals, see the small business acquisition due diligence guide.

Key Due Diligence Items for Medical Supply Deals

Medical supply diligence has a standard SMB layer (financials, contracts, HR) and a healthcare-specific layer. Don't skip the healthcare layer — it's where the deal-killers live.

**Customer contract review:** Who are the top 10 customers by revenue? What percentage is purchase order-based (no contract) vs. master service agreement? Is there a single hospital system representing more than 15% of revenue? Hospital systems have procurement review cycles — a new ownership change may trigger a re-procurement event.

**Reimbursement rate analysis (DME/HME):** Pull the Medicare fee schedule for every product category in the billing mix. CMS reimbursement rates for DME have been declining under competitive bidding. Project EBITDA under a scenario where reimbursement rates drop 10% — does the business still service SBA debt at 1.25x DSCR?

**Supplier contracts:** Are there exclusive distribution agreements with manufacturers or GPOs? Do those agreements have change of control provisions that allow termination? Losing an exclusive distribution agreement post-close is a material revenue risk.

**Inventory valuation:** Medical supply inventory includes products with expiration dates. Get a full physical count and confirm no obsolete or near-expiry stock is included in the purchase price. Negotiate a dollar-for-dollar price adjustment for any inventory that expires within 90 days of close.

• Customer concentration — no single account above 15% of revenue
• Reimbursement rate sensitivity — model 10% CMS rate reduction
• Supplier contract change of control provisions
• Physical inventory count with expiry date analysis
• GPO contract assignment terms — confirmed in writing from GPO directly
• DEA/FDA/CMS license transfer timeline and closing condition structure